Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$27.91 +0.3%	$31.76	$22.90 ▼ $36.45	$4.60B	0.39	1.76 million shs	1.52 million shs
BIIB Biogen	$119.12 +0.2%	$132.12	$110.04 ▼ $238.00	$17.44B	0.06	1.35 million shs	1.35 million shs
BMRN BioMarin Pharmaceutical	$62.98 -0.5%	$66.35	$52.93 ▼ $94.85	$12.02B	0.3	1.87 million shs	1.58 million shs
UTHR United Therapeutics	$297.04 +1.9%	$307.00	$233.31 ▼ $417.82	$13.34B	0.63	447,897 shs	410,281 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+2.91%	-16.17%	-11.68%	+12.80%
BIIB Biogen	0.00%	+0.19%	-14.11%	-20.11%	-43.11%
BMRN BioMarin Pharmaceutical	0.00%	+6.98%	-11.39%	+2.43%	-21.76%
UTHR United Therapeutics	0.00%	+2.34%	-5.08%	-21.15%	+24.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.6212 of 5 stars	4.3	1.0	4.2	3.0	2.5	1.9
BIIB Biogen	4.755 of 5 stars	4.2	3.0	3.7	3.3	2.5	1.9
BMRN BioMarin Pharmaceutical	4.92 of 5 stars	4.3	3.0	3.3	3.5	2.5	3.1
UTHR United Therapeutics	4.8981 of 5 stars	3.3	4.0	4.6	2.9	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.58	Moderate Buy	$38.08	36.45% Upside
BIIB Biogen	2.39	Hold	$203.07	70.48% Upside
BMRN BioMarin Pharmaceutical	2.70	Moderate Buy	$93.14	47.89% Upside
UTHR United Therapeutics	2.67	Moderate Buy	$390.17	31.35% Upside

Current Analyst Ratings Breakdown

Latest ALKS, BIIB, UTHR, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/28/2025	ALKS Alkermes	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
4/28/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform
4/28/2025	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$118.00
4/28/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$38.00 ➝ $33.00
4/25/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/25/2025	UTHR United Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$395.00 ➝ $314.00
4/23/2025	BIIB Biogen	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$219.00 ➝ $197.00
4/22/2025	BIIB Biogen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$221.00 ➝ $225.00
4/21/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$357.00 ➝ $355.00
4/21/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$314.00 ➝ $314.00
4/16/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	2.95	$2.10 per share	13.32	$9.05 per share	3.08
BIIB Biogen	$9.68B	1.80	$19.56 per share	6.09	$114.71 per share	1.04
BMRN BioMarin Pharmaceutical	$2.85B	4.21	$2.97 per share	21.17	$29.69 per share	2.12
UTHR United Therapeutics	$2.88B	4.64	$17.86 per share	16.63	$127.35 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.17	12.86	20.37	2.20	23.57%	30.80%	19.09%	5/1/2025 (Estimated)
BIIB Biogen	$1.63B	$11.19	10.65	7.22	1.51	16.87%	14.98%	8.76%	5/1/2025 (Estimated)
BMRN BioMarin Pharmaceutical	$167.65M	$2.20	28.63	14.44	0.61	14.96%	9.91%	7.65%	5/1/2025 (Estimated)
UTHR United Therapeutics	$984.80M	$24.60	13.05	10.81	0.97	40.31%	19.22%	16.15%	4/30/2025 (Estimated)

Latest ALKS, BIIB, UTHR, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	N/A	N/A	N/A	$307.53 million	N/A
5/1/2025	Q1 2025	BIIB Biogen	$3.59	N/A	N/A	N/A	$2.25 billion	N/A
5/1/2025	Q1 2025	BMRN BioMarin Pharmaceutical	$0.95	N/A	N/A	N/A	$741.84 million	N/A
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	N/A	N/A	N/A	$726.82 million	N/A
2/26/2025	Q4 2024	UTHR United Therapeutics	$6.10	$6.19	+$0.09	$6.19	$734.74 million	$735.90 million
2/19/2025	Q4 2024	BMRN BioMarin Pharmaceutical	$0.54	$0.72	+$0.18	$0.64	$711.05 million	$747.31 million
2/12/2025	Q4 2024	ALKS Alkermes	$0.81	$0.92	+$0.11	$0.88	$379.74 million	N/A
2/12/2025	Q4 2024	BIIB Biogen	$3.43	$3.44	+$0.01	$1.83	$2.42 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.04	2.65
BIIB Biogen	0.27	1.35	0.90
BMRN BioMarin Pharmaceutical	0.11	5.33	2.62
UTHR United Therapeutics	N/A	4.58	4.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
BIIB Biogen	87.93%
BMRN BioMarin Pharmaceutical	98.71%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
BIIB Biogen	0.16%
BMRN BioMarin Pharmaceutical	0.85%
UTHR United Therapeutics	11.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,280	164.84 million	154.66 million	Optionable
BIIB Biogen	8,720	146.38 million	146.14 million	Optionable
BMRN BioMarin Pharmaceutical	3,080	190.80 million	187.06 million	Optionable
UTHR United Therapeutics	980	44.91 million	39.33 million	Optionable

ALKS, BIIB, UTHR, and BMRN Headlines

Recent News About These Companies

Nitorum Capital L.P. Has $33.67 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 6:46 AM | marketbeat.com

Susquehanna Fundamental Investments LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 6:45 AM | marketbeat.com

Nebula Research & Development LLC Invests $1.62 Million in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 6:17 AM | marketbeat.com

Dark Forest Capital Management LP Makes New $540,000 Investment in United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 5:07 AM | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by TD Waterhouse Canada Inc.

April 28 at 4:45 AM | marketbeat.com

Canada Pension Plan Investment Board Sells 13,000 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 4:18 AM | marketbeat.com

Jump Financial LLC Buys Shares of 1,046 United Therapeutics Co. (NASDAQ:UTHR)

April 28 at 4:10 AM | marketbeat.com

Wells Fargo & Company Reaffirms Equal Weight Rating for United Therapeutics (NASDAQ:UTHR)

April 28 at 2:13 AM | americanbankingnews.com

Wells Fargo & Company Reiterates Equal Weight Rating for United Therapeutics (NASDAQ:UTHR)

April 27 at 8:29 AM | marketbeat.com

Lord Abbett & CO. LLC Raises Holdings in United Therapeutics Co. (NASDAQ:UTHR)

April 27 at 6:56 AM | marketbeat.com

Hancock Whitney Corp Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

April 27 at 6:18 AM | marketbeat.com

Hsbc Holdings PLC Lowers Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

April 27 at 5:28 AM | marketbeat.com

Tower Research Capital LLC TRC Acquires 2,233 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 27 at 5:00 AM | marketbeat.com

NewEdge Advisors LLC Grows Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

April 27 at 4:12 AM | marketbeat.com

United Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo

April 26 at 11:20 AM | markets.businessinsider.com

United Therapeutics (UTHR) was downgraded to a Hold Rating at Wells Fargo

April 26 at 11:20 AM | markets.businessinsider.com

Wells Fargo Downgrades United Therapeutics (UTHR)

April 26 at 11:20 AM | msn.com

Pinebridge Investments L.P. Purchases 7,558 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 26 at 6:01 AM | marketbeat.com

2UTHR : Demystifying United Therapeutics: Insights From 4 Analyst Reviews

April 25 at 1:20 PM | benzinga.com

This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

April 25 at 8:55 AM | benzinga.com

Fuller & Thaler Asset Management Inc. Sells 35,478 Shares of United Therapeutics Co. (NASDAQ:UTHR)

April 25 at 6:43 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Signs of a more buyer-friendly housing market emerge for the spring homebuying season
By The Associated Press | April 6, 2025
View Signs of a more buyer-friendly housing market emerge for the spring homebuying season
United States Steel's Crash: An Unmissable Buying Opportunity
By Gabriel Osorio-Mazilli | April 11, 2025
View United States Steel's Crash: An Unmissable Buying Opportunity
Cintas Ends UniFirst Talks—What’s Next for UNF Stock?
By Thomas Hughes | April 5, 2025
View Cintas Ends UniFirst Talks—What’s Next for UNF Stock?

ALKS, BIIB, UTHR, and BMRN Company Descriptions

Alkermes NASDAQ:ALKS

$27.91 +0.07 (+0.25%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$27.63 -0.28 (-1.00%)

As of 04/28/2025 07:56 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Biogen NASDAQ:BIIB

$119.12 +0.28 (+0.24%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$119.42 +0.30 (+0.25%)

As of 04/28/2025 07:37 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioMarin Pharmaceutical NASDAQ:BMRN

$62.98 -0.32 (-0.51%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$62.96 -0.02 (-0.04%)

As of 04/28/2025 04:54 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

United Therapeutics NASDAQ:UTHR

$297.04 +5.66 (+1.94%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$296.94 -0.11 (-0.04%)

As of 04/28/2025 06:42 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time